A Phase I, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability, food effect and pharmacokinetics of single and repeat doses of FT011 administered orally to healthy volunteers and patients with diabetic nephropathy associated with Type 2 diabetes

Trial Profile

A Phase I, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability, food effect and pharmacokinetics of single and repeat doses of FT011 administered orally to healthy volunteers and patients with diabetic nephropathy associated with Type 2 diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs SHP 627 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Fibrotech Therapeutics
  • Most Recent Events

    • 12 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top